Ultime notizie per Bank of Ireland Gr (OTC:BKRIF) Azioni

Bank of Ireland Group PLC is an Irish financial services group operating mostly in Ireland and the United Kingdom. Services include mortgages, business, and corporate lending, term loans, leasing, foreign exchange, life assurance, and pension products, among others. The bank's trading divisions include Retail Ireland, Wealth and Insurance, Retail UK, Corporate and Treasury (C&T), and Group Centre. The bank generates the majority of its revenue from Retail Ireland and serves consumer and business customers across a broad range of segments and sectors. Revenue is also derived from fees for a range of banking and transaction services. The bank has access to distribution in the United Kingdom via its relationship as a financial services partner with the nation's post office.

BANK IRELAND GRP EUR1 ORD by Bank Ireland Group PLC

Bank of Ireland Group PLC

Trump announced a US-China trade deal via the official <a href="https://whitehouse.gov/?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=us-china-trade-deal-announced" target="_blank" rel="noreferrer noopener">WhiteHouse.gov</a> site.
One man. One headline.
That's all it took to send us spiraling into one of the fastest bear markets in history… and now, it looks like we're headed for one of the fastest rallies back to all-time highs.
So what does this mean?
What did we learn?
Honestly… maybe nothing.
But if we look closer, here's what matters:
The market didn't care about rate cuts, jobs, or inflation. It only cared about tariffs. Specifically, two players… China and the EU.
Why?
China is the largest importer to the US. The EU? The 2nd biggest buyer of American goods, especially natural resources. American exporters… and many of our largest corporations… are vulnerable without deals in place.
<figure class="wp-block-image"><img decoding="async" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/4f2ec6e6-b0d2-45c1-af8b-6e5a9246b1b7/Screenshot_2025-05-11_at_5.36.19_PM.png?t=1746999384" alt="" /></figure>
Now that a deal with China is official, and a UK deal already in place…
An EU deal seems almost inevitable. Probably within weeks.
So what now?
Markets are poised to gap way above the 200-day moving average this week.
<figure class="wp-block-image"><img decoding="async" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/e9207cc0-caba-4bab-ae9b-b3c0539fa821/Screenshot_2025-05-11_at_5.37.00_PM.png?t=1746999424" alt="" /></figure>
$SPY and $QQQ are leading the charge… while the $IWM is still lagging. That won't change unless this rally extends through the rest of the month.
Yes, a recession could still be on the table… but let's be real:
If it happens, it'll be shallow. And we could be sitting near all-time highs as it's announced.
Why?
Because markets bottom long before recessions are ever declared.
So yeah… Monday's about to be green.
And "Sell in May and go away"?
Nah… this might be Make a Deal and Go All In.
We'll find out soon enough.
The S&amp;P 500 is down -3.7% YTD, but my portfolio? Up +5.9%.
What's working? Cybersecurity and fintech.
These sectors are least exposed to tariffs… and I've been buying them aggressively during this historic drop.
&#x2A;&#x2A;
Welcome to the WOLF Financial Newsletter.
Join over 18,000 savvy investors building wealth and mastering advanced investing strategies live on Twitter Spaces. Subscribe below to be part of the action:
<a target="_blank" rel="noreferrer noopener" href="https://marketmadness-newsletter.beehiiv.com/subscribe">Subscribe</a>
WOLF Financial has driven liquidity, user growth, and brand awareness across TradFi and Crypto through marketing, advisory, and partnership services. See more&nbsp;<a href="https://wolf.financial/?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=newsletter&amp;utm_campaign=new-post" target="_blank" rel="noreferrer noopener">Here</a>.

Equities

Government

Long Ideas

Broad U.S. Equity ETFs

Econ #s

Opinion

Markets

Trading Ideas

One Man, One Headline Was All It Took To Flip The Market

The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have advised a temporary halt in administering the chikungunya vaccine Valneva SE&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) Ixchiq to adults aged 60 and older as they investigate reports of serious adverse events, including neurological and cardiac complications, following vaccination.
As of May 7, 2025, 17 serious adverse events, including two deaths, have been <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-and-cdc-recommend-pause-use-ixchiq-chikungunya-vaccine-live-individuals-60-years-age-and-older" rel="noreferrer noopener">reported</a> globally among recipients aged 62 to 89.
Six of those reports originated from the United States, the agencies said in a recommendation on Friday.
Many affected individuals had underlying chronic medical conditions, though it remains unclear whether the vaccine directly caused the adverse reactions.
About 80,000 doses of Ixchiq have been distributed worldwide.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42296574/valnevas-chikungunyas-shot-shows-strong-long-lasting-antibody-persistence-at-three-years-comparable-in-older-and-younger-adults" rel="noreferrer noopener">Valneva&#8217;s Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults</a>
The vaccine, approved by the Food and Drug Administration (FDA) in November 2023, contains a live, weakened version of the chikungunya virus and is intended for adults 18 and older at risk of exposure.
During clinical trials involving roughly 3,500 participants in North America, the most commonly reported side effects were headache, fatigue, joint and muscle pain, fever, nausea, and injection site tenderness.
Although rare in the trials, severe reactions resembling chikungunya disease occurred in 1.6% of vaccinated participants, with two individuals requiring hospitalization.
The Vaccine Adverse Event Reporting System (VAERS), jointly managed by the FDA and the Centers for Disease Control and Prevention (CDC), is gathering and analyzing these cases.
In response to these concerns, the FDA is conducting a new benefit-risk assessment specifically for individuals 60 years and older.
In the first quarter of 2025, Ixchiq sales increased to 3 million euros from 0.2 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45244011/valneva-reports-first-quarter-2025-financial-results-and-provides-corporate-updates" rel="noreferrer noopener">euros a year ago</a>.
<ul class="wp-block-list">
<li>Sales include a very small number of the 40,000 doses Valneva supplied to La Réunion to respond to the chikungunya outbreak, as the large majority were only shipped in April 2025.</li>
</ul>
In April, France&#8217;s national health agency updated its advice on using Ixchiq after reports of serious side effects in older people with other health conditions during a vaccination campaign in La Réunion and Mayotte, where there is currently a major chikungunya outbreak with around 40,000 confirmed <a href="https://www.benzinga.com/pressreleases/25/04/g45027691/valneva-provides-update-on-recommendation-for-use-of-its-chikungunya-vaccine-by-french-authorities" target="_blank" rel="noreferrer noopener">cases so far in 2025</a>.
Initially, French health officials focused on vaccinating people aged 65 and older, especially those with existing health problems. But they paused the use of Ixchiq for this age group after three people over 80 were hospitalized with serious side effects following vaccination, one of whom died. All three had other health conditions.
In April, the Brazilian Health Regulatory Agency approved Ixchiq&nbsp;for individuals <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44798557/brazil-approves-valnevas-mosquito-borne-chikungunya-vaccine" rel="noreferrer noopener">18 and older</a>.
In January, Valneva reported Phase 3 data in adolescents for its single-shot <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43102451/valneva-chikungunya-vaccine-shows-high-sustained-immune-response-in-adolescents-one-year-after-si" rel="noreferrer noopener">chikungunya virus vaccine</a>.
The vaccine showed a 98.3% sero-response rate one year after the single vaccination.
Price Action: VALN stock is down 0.08% at $6.47 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45352601/nano-cap-cytomx-therapeutics-stock-surges-on-heels-of-cancer-data-report" target="_blank" rel="noreferrer noopener">Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report</a></li>
</ul>
Photo: Shutterstock

Biotech

News

Health Care

General

VALN

US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events

Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) with a Overweight and lowers the price target from $4.5 to $4.

Price Target

Analyst Ratings

NSPR

Piper Sandler Maintains Overweight on InspireMD, Lowers Price Target to $4

Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $205 to $210.

Piper Sandler Maintains Overweight on Zoetis, Raises Price Target to $210

Piper Sandler analyst Richard Repetto upgrades Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) from Neutral to Overweight and maintains the price target from $30 to $30.

Upgrades

FRGE

Piper Sandler Upgrades Forge Global Holdings to Overweight, Maintains Price Target to $30

BMO Capital analyst Keith Bachman maintains Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) with a Market Perform and lowers the price target from $3 to $2.25.

BMO Capital Maintains Market Perform on Telos, Lowers Price Target to $2.25

<a href="https://www.wsj.com/business/telecom/fcc-threatens-charlie-ergens-hold-on-satellite-5g-spectrum-licenses-e2913889?msockid=21c662101c496b42343370ae1de86aaa">https://www.wsj.com/business/telecom/fcc-threatens-charlie-ergens-hold-on-satellite-5g-spectrum-licenses-e2913889?msockid=21c662101c496b42343370ae1de86aaa</a>

SATS

'FCC Threatens Charlie Ergen's Hold on Satellite, 5G Spectrum Licenses'- WSJ

BMO Capital analyst Keith Bachman maintains TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) with a Market Perform and lowers the price target from $4.5 to $3.

TIXT

BMO Capital Maintains Market Perform on TELUS Intl, Lowers Price Target to $3

WIIM

BAOS

CARG

CDLX

FENG

FUBO

GOGO

GOOG

GOOGL

GSAT

GXAI

MGNI

NTES

PINS

RBLX

RDDT

ROKU

SNAP

SPHR

VEON

WIMI

Shares of companies within the broader communication services sector are trading higher amid overall market strength after the US and China agreed to a temporary reduction in most tariffs on each other's goods.

BMO Capital analyst Andrew Strelzik maintains Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) with a Market Perform and lowers the price target from $8 to $7.

GPRE

BMO Capital Maintains Market Perform on Green Plains, Lowers Price Target to $7

AVNT

AXTA

CENX

MATV

MEOH

MTUS

PACK

TANH

TROX

Shares of companies within the broader materials sector are trading higher amid overall market strength after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A decrease of trade tensions could reduce demand uncertainty for materials.

PPTA

Perpetua Resources shares are trading lower after the company reported worse-than-expected Q1 EPS results.

BMO Capital analyst Rufus Hone maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Outperform and raises the price target from $44 to $45.

TOST

BMO Capital Maintains Outperform on Toast, Raises Price Target to $45

BMO Capital analyst James Thalacker maintains Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) with a Outperform and raises the price target from $78 to $81.

BMO Capital Maintains Outperform on Sempra, Raises Price Target to $81

BMO Capital analyst Jeff Silber maintains Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) with a Outperform and raises the price target from $339 to $355.

MORN

BMO Capital Maintains Outperform on Morningstar, Raises Price Target to $355

BMO Capital analyst Evan Seigerman maintains Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Outperform and raises the price target from $112 to $120.

IRON

BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

CSTM

SCCO

STLD

TECK

Shares of metals stocks are trading higher amid overall market strength after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A decrease of trade tensions could reduce demand uncertainty for base metals.

BMO Capital analyst Joel Jackson maintains Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) with a Market Perform and raises the price target from $15 to $20.

BMO Capital Maintains Market Perform on Compass Minerals Intl, Raises Price Target to $20

BMO Capital analyst James Thalacker maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Outperform and raises the price target from $291 to $337.

BMO Capital Maintains Outperform on Constellation Energy, Raises Price Target to $337

BMO Capital analyst Jeffrey Silber maintains Adtalem Glb Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) with a Outperform and raises the price target from $115 to $132.

Adtalem Global Education Inc. Common Stock

ATGE

BMO Capital Maintains Outperform on Adtalem Glb Education, Raises Price Target to $132

Bank of Ireland Gr

Comments

Bank of Ireland Gr

Notizie

Ultime notizie per Bank of Ireland Gr (OTC:BKRIF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO